Ignite Creation Date:
2024-05-06 @ 6:57 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05846516
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-04-18
Brief Title:
A Study to Evaluate ATP150ATP152 VSV-GP154 and Ezabenlimab in Patients With KRAS G12DG12V Mutated PDAC KISIMA-02
Sponsor:
Amal Therapeutics
Organization:
Amal Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pancreatic Ductal Adenocarcinoma |
Keywords:
| Name | View |
|---|---|
| LAPC | View |
| KISIMA-02 | View |
| PDAC | View |
| ATP150 | View |
| ATP152 | View |
| Ezabenlimab | View |
| VSV-GP154 | View |
| Adjuvant setting | View |
| Resected pancreatic ductal adenocarcinoma | View |
| Metastatic pancreatic ductal adenocarcinoma | View |
| Locally advanced pancreatic ductal adenocarcinoma | View |
| Resected PDAC | View |
| Metastatic PDAC | View |